SCHEMBL460246

SCHEMBL460246

N#Cc1cccc(-c2oc(C(=O)N3CCNC(=O)C3)cc2-c2cccc(Cl)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 4/20 0.40
PDE4B Q07343 2/20 0.39
HSP90AA1 P07900 1/20 0.38
SCN9A Q15858 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE4D Q08499 1/20 0.36
UTS2R Q9UKP6 1/20 0.36
HSD17B3 P37058 1/20 0.36
BRAF P15056 1/20 0.36
SLC6A7 Q99884 1/20 0.36
PARP1 P09874 1/20 0.35
GRM5 P41594 1/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419600 0.92 PDE4B (0.44) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL421343 0.91 PGR (0.39) EIF4A3PDE4BHSP90AA1SCN9AGAA
SCHEMBL419357 0.91 METAP2 (0.36) EIF4A3PDE4BHSP90AA1SCN9AUTS2R
SCHEMBL455596 0.89 PDE4B (0.37) PDE4BHSP90AA1SCN9AGAARAB9A
SCHEMBL421535 0.87 PDE4B (0.41) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL416921 0.86 PDE4B (0.40) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL417650 0.85 HSP90AA1 (0.40) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL421281 0.85 PDE4B (0.41) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL418361 0.85 PDE4B (0.41) PDE4BHSP90AA1GAARAB9ASMN1; SMN2
SCHEMBL418318 0.85 PDE4B (0.41) PDE4BHSP90AA1GAARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
EP-2376479-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AiCuris GmbH & Co. KG (DE) 2011-10-19 EP disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT EIF4A3 2020/4885PDE4B 1900/4885HSP90AA1 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.